Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Frontiers in Endocrinology|December 11, 2023
<i>PAM</i> variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomasSunita M C De Sousa, Angeline Shen, Christopher J Yates, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|December 19, 2018
An Update on Addison's DiseaseAndreas Barthel, Georg Benker, Kai Berens, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|December 22, 2024
Mass spectrometric detection of neutrophil elastase cleaved corticosteroid binding globulin and its association with Asn347 site glycosylation, in septic shock patientsJessica H Lee, Zeynep Sumer-Bayraktar, Parul Mittal, et al.
Endocrine Pathology|September 2, 2019
The Genomic Landscape of Sporadic ProlactinomasSunita M C De Sousa, Paul P S Wang, Stephen Santoreneos, et al.
The Journal of Clinical Endocrinology and Metabolism|July 29, 2011
Clinical manifestations of highly prevalent corticosteroid-binding globulin mutations in a village in southern ItalyGiovanni Cizza, Livia Bernardi, Nicoletta Smirne, et al.
The Medical Journal of Australia|May 17, 2022
The clinical and genetic features of hereditary pancreatitis in South AustraliaDenghao Wu, Tristan J Bampton, Hamish S Scott, et al.
Journal of the Endocrine Society|November 16, 2020
Aberrant Splicing of <i>SDHC</i> in Families With Unexplained Succinate Dehydrogenase-Deficient ParagangliomasSunita M C De Sousa, John Toubia, Tristan S E Hardy, et al.
The Journal of Clinical Endocrinology and Metabolism|June 7, 2014
ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasiaLucia Gagliardi, Andreas W Schreiber, Christopher N Hahn, et al.
Endocrinology|January 12, 2026
Harnessing native corticosteroid-binding globulin to treat life-threatening septic shockStewart D Ramsay, Declan E Kilgariff, Benjamin J Young, et al.
European Journal of Endocrinology|May 24, 2018
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegalyPeter J Trainer, John D C Newell-Price, John Ayuk, et al.
Pageof 13